Millie Nelson

Pharma is being more selective in the deals it strikes among what a panel of experts say is an abundance of players looking to partner.

Investors at LSX Investival discuss how, after securing Series A funding, biotech companies should begin to lay the groundwork for Series B financing.

Novo Nordisk's rapid growth marks its success, but firm veteran Tomas Landh said it comes at a cost, such as tension bred through acquisitions.

In a bid to bolster its efforts in the gene therapy and neuroscience space, Novartis has acquired Kate Therapeutics for up to $1.1 billion.

The LSX European Lifestars Awards (ELAs) in London, UK gathered life science executives and partners to celebrate their achievements over the past 12 months.

Better data equals better solutions said panelists at LSX Nordics Congress, but collaborations must create behavioral changes to drive innovation.

Bayer will provide facility access and tailored mentorship at its recently opened life science incubator, Co.Lab.

MFX, Tolemy Bio, and AminoAcids join forces to advance model-driven media optimization for cell and gene therapies.

We sat down with Judy Chou, CEO of AllTruBio, to delve into the details of the company’s recent $225 million Series B financing round.

The acquisition will see AbbVie gain Nimble Therapeutics’ lead candidate, an oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis.